List of Skyclarys drug patents
Skyclarys is owned by Reata Pharms.
Skyclarys contains Omaveloxolone.
Skyclarys has a total of 6 drug patents out of which 0 drug patents have expired.
Skyclarys was authorised for market use on 28 February, 2023.
Skyclarys is available in capsule;oral dosage forms.
Skyclarys can be used as treatment of friedreich's ataxia in adults and adolescents aged 16 years and older.
Drug patent challenges can be filed against Skyclarys from 2027-02-28.
The generics of Skyclarys are possible to be released after 24 April, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9670147 | REATA PHARMS | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
Apr, 2029
(5 years from now) | |
| US8124799 | REATA PHARMS | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
Dec, 2029
(6 years from now) | |
| US8993640 | REATA PHARMS | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
Apr, 2033
(9 years from now) | |
| US9701709 | REATA PHARMS | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
Apr, 2033
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8440854 | REATA PHARMS | Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 |
Apr, 2029
(5 years from now) | |
| US11091430 | REATA PHARMS | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
Apr, 2029
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Feb 28, 2030 |
| New Chemical Entity Exclusivity (NCE) | Feb 28, 2028 |
Drugs and Companies using OMAVELOXOLONE ingredient
NCE-1 date: 2027-02-28
Market Authorisation Date: 28 February, 2023
Treatment: Treatment of friedreich's ataxia in adults and adolescents aged 16 years and older
Dosage: CAPSULE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic